The global Daptomycin Market is currently valued at approximately $3.78 billion in 2026, driven by the escalating crisis of antimicrobial resistance (AMR). As a "last-resort" antibiotic, Daptomycin remains a vital tool for treating life-threatening Gram-positive infections. Technological Advancements in Delivery The most significant news in 2026 involves the breakthrough of biomimetic nano-drug...